Nathalie Huitorel - Genfit SA Insider

GNFTF -- USA Stock  

USD 27.79  0.54  1.98%

  Executive
Ms. Nathalie Huitorel has served as Executive Vice President of Finance and Member of the Management Board of Genfit SA since July 3, 2008. She previously served as Financial and Administrative Director of the Company from October 2007 to July 3, 2008. She has previously worked in multiple operational functions in technology based companies. For the past 10 years, she had been Financial Director of MS COMPOSITES. Prior to that, she was involved in the listing process of FINUCHEM on the stock market and has led various mergers and acquisitions. She is a graduate of Ecole Superieure de Commerce de Lille.
Age: 55  Executive Since 2008      
33 3 20 16 40 00  http://www.genfit.com

Management Efficiency

The company has return on total asset (ROA) of (15.42) % which means that it has lost $15.42 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (47.45) % meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 190.77 M in total debt with debt to equity ratio (D/E) of 157.1 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Genfit SA has Current Ratio of 10.25 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.

Similar Executives

Found 11 records

EXECUTIVE Since

Rolando SiatelaMegaworld Corporation
N/A
Yong ZhengCHINA LIFE INSURANCE LTD
2013
Joseph LacsonMetro Pacific Investments Corpo
2016
Anna LlovidoMegaworld Corporation
2014
Qi RuanCHINA LIFE INSURANCE LTD
2016
Jiade LiuCHINA LIFE INSURANCE LTD
2015
Johann QuiazonMegaworld Corporation
2017
Cheryll SerenoMegaworld Corporation
2018
Zhong ZhanCHINA LIFE INSURANCE LTD
1968
Mingguang LiCHINA LIFE INSURANCE LTD
2017
Cristina GilFernandezMetro Pacific Investments Corpo
2013

Entity Summary

Genfit SA, a biopharmaceutical company, develops therapeutic and diagnostic solutions to address high unmet patient needs in metabolic and inflammatory diseases, with a particular focus on the liver worldwide. Genfit SA was founded in 1999 and is headquartered in Loos, France. Genfit SA operates under Biotechnology classification in USA and traded on OTC Market. It employs 125 people.Genfit SA (GNFTF) is traded on OTC Market in USA. It is located in Parc Eurasant? and employs 125 people.

Genfit SA Leadership Team

Dean Hum, COO, Chief Scientific Officer and Member of The Executive Board
Charles Woler, Vice Chairman of the Supervisory Board
Florence Sejourne, Member of the Supervisory Board, Representative of Biotech Avenir
Frederic Desdouits, Member of the Supervisory Board
Nathalie Huitorel, Chief Financial and Admin. Officer and Member of The Executive Board
Philippe Moons, Member of the Supervisory Board, Representative of Finorpa
Bart Staels, President of the Scientific Advisory Board, Member of the Management Board
Xavier Buttes, Chairman of the Supervisory Board
JeanFrancois Mouney, Chairman of the Management Board, CEO

Stock Performance Indicators

Current Sentiment - GNFTF

Genfit SA Investor Sentiment

Macroaxis portfolio users are indifferent in their judgment towards investing in Genfit SA. What is your judgment towards investing in Genfit SA? Are you bullish or bearish?
Bullish
Bearish
50% Bullish
50% Bearish
Skip

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please also check Risk vs Return Analysis. Please also try Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Search macroaxis.com